Integrating oral semaglutide into clinical practice in primary care: for whom, when, and how?

References

• Aroda VR, Rosenstock J, Terauchi Y, et al. PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care. 2019;42(9):1724–1732.
   PubMed Web of Science ®Google Scholar
• Mosenzon O, Blicher TM, Rosenlund S, et al. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019;7(7):515–527.
   PubMed Web of Science ®Google Scholar
• Pieber TR, Bode B, Mertens A, et al. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019;7(7):528–539.
   PubMed Web of Science ®Google Scholar
• Pratley R, Amod A, Hoff ST, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019;394(10192):39–50.
   PubMed Web of Science ®Google Scholar
• Rodbard HW, Rosenstock J, Canani LH, et al. Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial. Diabetes Care. 2019;42(12):2272–2281.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Allison D, Birkenfeld AL, et al. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial. JAMA. 2019;321(15):1466–1480.
   PubMed Web of Science ®Google Scholar
• Zinman B, Aroda VR, Buse JB, et al. Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PIONEER 8 trial. Diabetes Care. 2019;42(12):2262–2271.
   PubMed Web of Science ®Google Scholar
• Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841–851.
   PubMed Web of Science ®Google Scholar
• Rybelsus® (semaglutide) prescribing information [updated Jan 2020; cited 2020 May 25]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213182s000,213051s001lbl.pdf
   Google Scholar
• American Diabetes Association. 11. Microvascular complications and foot care: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S135–S151.
   PubMed Web of Science ®Google Scholar
• Dahl K, Blundell J, Gibbons C, et al. Oral semaglutide improves postprandial glucose and lipid metabolism and delays first-hour gastric emptying in subjects with type 2 diabetes (Abstract). Diabetologia. 2019;62(Suppl 1):50.
   Google Scholar
• Novo Nordisk. Rybelsus® (oral semaglutide) approved for the treatment of adults with type 2 diabetes in the EU. 2020 [cited 2020 May 25] Available from: https://www.novonordisk.com/media/news-details.2277630.html
   Google Scholar
• Bydureon® (exenatide extended-release) prescribing information [updated Feb 2020; cited 2020 May 25]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022200s030lbl.pdf
   Google Scholar
• Victoza® (liraglutide) prescribing information [updated Jun 2019; cited 2020 May 25]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022341s031lbl.pdf
   Google Scholar
• Adlyxin® (lixisenatide) prescribing information [updated Jan 2019; cited 2020 May 25]. Available from: http://products.sanofi.us/Adlyxin/Adlyxin.pdf
   Google Scholar
• Byetta® (exenatide) prescribing information [updated Feb 2020; cited 2020 May 25]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021773s043lbl.pdf
   Google Scholar
• Ozempic® (semaglutide) prescribing information [updated Jan 2020; cited 2020 May 25]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209637s003lbl.pdf
   Google Scholar
• Trulicity® (dulaglutide) prescribing information [updated Feb 2020; cited 2020 May 25]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125469s033lbl.pdf
   Google Scholar
• Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm – 2020 executive summary. Endocr Pract. 2020;26(1):107–139.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S98–S110.
   PubMed Web of Science ®Google Scholar
• Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255–323.
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Colhoun HM, Dagenais GR, et al. Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide. Diabetes Obes Metab. 2018;20(1):42–49.
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121–130.
   PubMed Web of Science ®Google Scholar
• Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomized placebo-controlled trial. Lancet. 2018;392(10157):1519–1529.
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322.
   PubMed Web of Science ®Google Scholar
• Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–1844.
   PubMed Web of Science ®Google Scholar
• Lavernia F, Blonde L. Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes compared with other oral antihyperglycemic agents and placebo. Postgrad Med. 2020;132(S2):15–25.
   Google Scholar
• Wright EE, Aroda VA. Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy. Postgrad Med. 2020;132(S2):26–36.
   Google Scholar
• U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. National diabetes statistics report 2020: estimates of diabetes and its burden in the United States. [cited 2020 May 25]. Available from: https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf
   Google Scholar
• American Diabetes Association. 8. Obesity management for the treatment of type 2 diabetes: Standards of Medical Care in Diabetes-2019. Diabetes Care. 2020;43(Suppl 1):S89–S97.
   PubMedGoogle Scholar
• Aroda VR, Saugstrup T, Buse JB, et al. Incorporating and interpreting regulatory guidance on estimands in diabetes clinical trials: the PIONEER 1 randomized clinical trial as an example. Diabetes Obes Metab. 2019;21(10):2203–2210.
   PubMed Web of Science ®Google Scholar
• Nauck MA, Meier JJ. Are all GLP-1 agonists equal in the treatment of type 2 diabetes? Eur J Endocrinol. 2019;181:R211–R234.
   PubMed Web of Science ®Google Scholar
• Saxenda® (liraglutide) prescribing information [updated Oct 2018; cited 2020 May 25]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206321s007lbl.pdf
   Google Scholar
• Lash RW, Lucas DO, Illes J. Preventing hypoglycemia in type 2 diabetes. J Clin Endocrinol Metab. 2018;103(4):1265–1268.
   PubMed Web of Science ®Google Scholar
• Yun JS, Ko SH. Risk factors and adverse outcomes of severe hypoglycemia in type 2 diabetes mellitus. Diabetes Metab J. 2016;40(6):423–432.
   PubMed Web of Science ®Google Scholar
• Amiel SA, Dixon T, Mann R, et al. Hypoglycaemia in type 2 diabetes. Diabet Med. 2008;25(3):245–254.
   PubMed Web of Science ®Google Scholar
• Moen MF, Zhan M, Hsu VD, et al. Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol. 2009;4(6):1121–1127.
   PubMed Web of Science ®Google Scholar
• Granhall C, Søndergaard FL, Thomsen M, et al. Pharmacokinetics, safety and tolerability of oral semaglutide in subjects with renal impairment. Clin Pharmacokinet. 2018;57(12):1571–1580.
   PubMed Web of Science ®Google Scholar
• Bui V, Neumiller JJ. Oral semaglutide. Clin Diabetes. 2018;36(4):327–329.
   PubMedGoogle Scholar
• Santos Cavaiola T, Kiriakov Y, Reid T. Primary care management of patients with type 2 diabetes: overcoming inertia and advancing therapy with the use of injectables. Clin Ther. 2019;41(2):352–367.
   PubMed Web of Science ®Google Scholar
• Miller E, Aguilar RB, Herman ME, et al. Type 2 diabetes: evolving concepts and treatment. Cleve Clin J Med. 2019;86(7):494–504.
   PubMed Web of Science ®Google Scholar
• Brunton SA, Wysham CH. GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date. Postgrad Med. 2020;132(S2):3–14.
   Google Scholar
• Buysman EK, Liu F, Hammer M, et al. Impact of medication adherence and persistence on clinical and economic outcomes in patients with type 2 diabetes treated with liraglutide: a retrospective cohort study. Adv Ther. 2015;32(4):341–355.
   PubMed Web of Science ®Google Scholar
• Divino V, Boye KS, Lebrec J, et al. GLP-1 RA treatment and dosing patterns among type 2 diabetes patients in six countries: a retrospective analysis of pharmacy claims data. Diabetes Ther. 2019;10(3):1067–1088.
   PubMed Web of Science ®Google Scholar
• Mody R, Grabner M, Yu M, et al. Real-world effectiveness, adherence and persistence among patients with type 2 diabetes mellitus initiating dulaglutide treatment. Curr Med Res Opin. 2018;34(6):995–1003.
   PubMed Web of Science ®Google Scholar
• Kruger DF, LaRue S, Estepa P. Recognition of and steps to mitigate anxiety and fear of pain in injectable diabetes treatment. Diabetes Metab Syndr Obes. 2015;8:49–56.
   PubMed Web of Science ®Google Scholar
• Lyseng-Williamson KA. Glucagon-like peptide-1 receptor analogues in type 2 diabetes: their use and differential features. Clin Drug Investig. 2019;39(8):805–819.
   PubMed Web of Science ®Google Scholar
• Okemah J, Peng J, Quiñones M. Addressing clinical inertia in type 2 diabetes mellitus: a review. Adv Ther. 2018;35:1735–1745.
   PubMed Web of Science ®Google Scholar
• Spain CV, Wright JJ, Hahn RM, et al. Self-reported barriers to adherence and persistence to treatment with injectable medications for type 2 diabetes. Clin Ther. 2016;38(7):1653–1664.
   PubMed Web of Science ®Google Scholar
• Davies M, Pieber TR, Hartoft-Nielsen ML, et al. Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial. JAMA. 2017;318(15):1460–1470.
   PubMed Web of Science ®Google Scholar
• Farxiga® (dapagliflozin) prescribing information [updated Jan 2020; cited 2020 May 25]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202293s022lbl.pdf
   Google Scholar
• Jardiance® (empagliflozin) prescribing information [updated Jan 2020; cited 2020 May 25]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204629s023lbl.pdf
   Google Scholar
• Invokana® (canagliflozin) prescribing information [updated Jan 2020; cited 2020 May 25]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204042s036lbl.pdf
   Google Scholar
• Bækdal TA, Thomsen M, Kupčová V, et al. Pharmacokinetics, safety, and tolerability of oral semaglutide in subjects with hepatic impairment. J Clin Pharmacol. 2018;58(10):1314–1323.
   PubMed Web of Science ®Google Scholar
• Mosenzon O, Miller EM, Warren ML. Oral semaglutide in patients with type 2 diabetes and cardiovascular disease, renal impairment, or other comorbidities, and in older patients. Postgrad Med. 2020;132(S2):37–47.
   Google Scholar
• Clinicaltrials.gov. A heart disease study of semaglutide in patients with type 2 diabetes (SOUL). Trial ID NCT03914326. [cited 2020 May 25]. Available from: https://clinicaltrials.gov/ct2/show/NCT03914326
   Google Scholar
• Aroda VR, Bauer R, Herts CL, et al. Efficacy and safety of oral semaglutide by baseline age in the PIONEER clinical trial program. Diabetes. 2020;69(Suppl 1):932-P.
   Google Scholar
• American Diabetes Association. 12. Older adults: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S152–S162.
   PubMedGoogle Scholar
• Reid TS. Practical use of glucagon-like peptide-1 receptor agonist therapy in primary care. Clin Diabetes. 2013;31(4):148–157.
   Google Scholar
• Altekruse S, Das A, Cho H, et al. Do US thyroid cancer incidence rates increase with socioeconomic status among people with health insurance? An observational study using SEER population-based data. BMJ Open. 2015;5(12):e009843.
   PubMed Web of Science ®Google Scholar
• Cabanillas ME, McFadden DG, Durante C. Thyroid cancer. Lancet. 2016;388(10061):2783–2795.
   PubMed Web of Science ®Google Scholar
• Olson E, Wintheiser G, Wolfe KM, et al. Epidemiology of thyroid cancer: a review of the National Cancer Database, 2000-2013. Cureus. 2019;11(2):e4127.
   PubMed Web of Science ®Google Scholar
• Stamatakos M, Paraskeva P, Stefanaki C, et al. Medullary thyroid carcinoma: the third most common thyroid cancer reviewed. Oncol Lett. 2011;2(1):49–53.
   PubMed Web of Science ®Google Scholar
• Cao C, Yang S, Zhou Z. GLP-1 receptor agonists and risk of cancer in type 2 diabetes: an updated meta-analysis of randomized controlled trials. Endocrine. 2019;66(2):157–165.
   PubMed Web of Science ®Google Scholar
• Guo X, Yang Q, Dong J, et al. Tumour risk with once-weekly glucagon-like peptide-1 receptor agonists in type 2 diabetes mellitus patients: a systematic review. Clin Drug Investig. 2016;36(6):433–441.
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhang X, Chai S, et al. Risk of malignant neoplasia with glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes: a meta-analysis. J Diabetes Res. 2019;2019:1534365.
   PubMed Web of Science ®Google Scholar
• Laiteerapong N, Ham SA, Gao Y, et al. The legacy effect in type 2 diabetes: impact of early glycemic control on future complications (the Diabetes & Aging Study). Diabetes Care. 2019;42(3):416–426.
   PubMed Web of Science ®Google Scholar
• Takao T, Matsuyama Y, Suka M, et al. Analysis of the duration and extent of the legacy effect in patients with type 2 diabetes: a real-world longitudinal study. J Diabetes Complications. 2019;33(8):516–522.
   PubMed Web of Science ®Google Scholar
• Khunti K, Seidu S. Therapeutic inertia and the legacy of dysglycemia on the microvascular and macrovascular complications of diabetes. Diabetes Care. 2019;42(3):349–351.
   PubMed Web of Science ®Google Scholar
• Haluzík M, Bauer R, Eriksson JW, et al. Efficacy of oral semaglutide according to diabetes duration: an exploratory subgroup analysis of the PIONEER trial programme (Abstract). Diabetologia. 2019;62(Suppl 1):49.
   Google Scholar
• Meier JJ, Bauer R, Blicher TM, et al. Efficacy of oral semaglutide according to baseline HbA1c: an exploratory subgroup analysis of the PIONEER trial programme (Abstract). Diabetologia. 2019;62(Suppl 1):51.
   Google Scholar
• Maarbjerg SJ, Borregaard J, Breitschaft A, et al. Evaluation of the effect of food on the pharmacokinetics of oral semaglutide. Presented at the American Diabetes Association, San Diego, California; 2017 Jun 9–13.
   Google Scholar
• Hauge C, Breitschaft A, Hartoft-Nielsen M-L, et al. A drug-drug interaction trial of oral semaglutide with levothyroxine and multiple coadministered tablets. J Endocr Soc. 2019;3(Suppl 1):SAT–140.
   Google Scholar
• Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association Task Force on thyroid hormone replacement. Thyroid. 2014;24(12):1670–1751.
   PubMed Web of Science ®Google Scholar
• Connor A, Donsmark M, Hartoft-Nielsen M-L, et al. A pharmacoscintigraphic study of the relationship between tablet erosion and pharmacokinetics of oral semaglutide. Diabetologia. 2017;60(Suppl 1):S361. Abstract 787.
   Google Scholar
• Milne N. How to use GLP-1 receptor agonist therapy safely and effectively. Diabetes Primary Care. 2019;21:45–46.
   Google Scholar
• Bækdal TA, Breitschaft A, Navarria A, et al. A randomized study investigating the effect of omeprazole on the pharmacokinetics of oral semaglutide. Expert Opin Drug Metab Toxicol. 2018;14:869–877.
   PubMed Web of Science ®Google Scholar
• Bækdal TA, Albayaty M, Manigandan E, et al. A trial to investigate the effect of oral semaglutide on the pharmacokinetics of furosemide and rosuvastatin in healthy subjects (Abstract). Diabetologia. 2018;61(Suppl 1):714.
   Google Scholar
• Bækdal TA, Borregaard J, Hansen CW, et al. Effect of oral semaglutide on the pharmacokinetics of lisinopril, warfarin, digoxin, and metformin in healthy subjects. Clin Pharmacokinet. 2019;58(9):1193–1203.
   PubMed Web of Science ®Google Scholar
• Jordy AB, Breitschaft A, Christiansen E, et al. Oral semaglutide does not affect the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel (Abstract). Diabetologia. 2018;61(Suppl 1):713.
   Google Scholar
• Levoxyl® (levothyroxine sodium) prescribing information [updated Nov 2018; cited 2020 May 25]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021301s038lbl.pdf
   Google Scholar
• Ellero C, Han J, Bhavsar S, et al. Prophylactic use of anti-emetic medications reduced nausea and vomiting associated with exenatide treatment: a retrospective analysis of an open-label, parallel-group, single-dose study in healthy subjects. Diabet Med. 2010;27(10):1168–1173.
   PubMed Web of Science ®Google Scholar
• Kalra S, Das AK, Sahay RK, et al. Consensus recommendations on GLP-1 RA use in the management of type 2 diabetes mellitus: South Asian task force. Diabetes Ther. 2019;10(5):1645–1717.
   PubMed Web of Science ®Google Scholar